サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1170949

ジェネリック医薬品受託製造市場の規模・シェア・動向分析 (2022-2030年)：医薬品タイプ (ブランド・非ブランド)・製品 (API・医薬品)・投与経路・用途別

Generic Pharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis Report By Drug Type (Branded, Unbranded), By Product (API, Drug Product), By Route Of Administration, By Application, And Segment Forecasts, 2022 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 100 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ジェネリック医薬品受託製造市場の規模・シェア・動向分析 (2022-2030年)：医薬品タイプ (ブランド・非ブランド)・製品 (API・医薬品)・投与経路・用途別
出版日: 2022年11月10日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のジェネリック医薬品受託製造の市場規模は、2022年から2030年にかけてCAGR5.8%で推移し、2030年には1,069億米ドルの規模に成長すると予測されています。

アウトソーシングの導入に伴うコスト削減や時間短縮のメリットが業界を牽引する要因となっています。また、世界的に見ると、慢性疾患患者が非常に多くなっています。慢性疾患は長期間の治療が必要であり、医薬品の価格が高いため、費用対効果の高いジェネリック医薬品への需要が高まっています。

当レポートでは、世界のジェネリック医薬品受託製造の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 ジェネリック医薬品受託製造市場の可変因子・動向・展望

  • 市場の見通し
  • 普及・成長の見通しのマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • PESTLE分析
    • 主要取引・戦略的提携の分析
  • COVID-19の影響・改革戦略

第4章 ジェネリック医薬品受託製造市場の推計・動向分析：薬剤タイプ別

  • 定義・範囲
  • 市場シェア分析：2021年・2030年
    • ブランドジェネリック
    • 非ブランドジェネリック

第5章 ジェネリック医薬品受託製造市場の推計・動向分析：製品別

  • 定義・範囲
  • 市場シェア分析：2021年・2030年
    • API
    • 医薬品

第6章 ジェネリック医薬品受託製造市場の推計・動向分析：投与経路別

  • 定義・範囲
  • 市場シェア分析：2021年・2030年
    • 経口剤
    • 非経口剤
    • 局所剤
    • その他

第7章 ジェネリック医薬品受託製造市場の推計・動向分析：用途別

  • 定義・範囲
  • 市場シェア分析：2021年・2030年
    • 腫瘍
    • 免疫
    • 糖尿病治療
    • 神経
    • 抗凝固剤
    • 心臓血管
    • 呼吸器
    • 疼痛
    • HIV抗ウイルス薬
    • その他

第8章 ジェネリック医薬品受託製造市場の推計・動向分析：地域別

  • 市場シェア分析：2021年・2030年
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競合分析

  • 主要参入企業による近年の展開・影響分析
  • 企業/競合上の分類
  • 参入企業の分類
  • ベンダー情勢

第10章 競合情勢

  • 企業プロファイル
    • Recipharm AB
    • Siegfried Holding AG
    • Aurobindo Pharma
    • Cambrex Corporation
    • Alcami Corporation, Inc.
    • Curia Global, Inc.
    • Catalent, Inc
    • Acme Generics Pvt Ltd.
    • Metric Contract Services
    • Syngene International Limited
    • Pfizer CentreOne;
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig 1 Market research process
  • Fig 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Volume Price Analysis
  • Fig. 10 Generic pharmaceuticals contract manufacturing market snapshot (2021)
  • Fig. 11 Generic pharmaceuticals contract manufacturing market segmentation
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 Generic pharmaceuticals contract manufacturing market drug type outlook: Segment dashboard
  • Fig. 18 Generic pharmaceuticals contract manufacturing market: Drug type movement analysis
  • Fig. 19 Branded Generics market (USD Billion)
  • Fig. 20 Unbranded Generics market (USD Billion)
  • Fig. 21 Generic pharmaceuticals contract manufacturing market product outlook: Segment dashboard
  • Fig. 22 Generic pharmaceuticals contract manufacturing market: Product movement analysis
  • Fig. 23 API market (USD Billion)
  • Fig. 24 Drug Product market (USD Billion)
  • Fig. 25 Generic pharmaceuticals contract manufacturing market route of adminsitration outlook: Segment dashboard
  • Fig. 26 Generic pharmaceuticals contract manufacturing market: Route of adminsitrationmovement analysis
  • Fig. 27 Oral market (USD Billion)
  • Fig. 28 Topical market (USD Billion)
  • Fig. 29 Parentral market (USD Billion)
  • Fig. 30 Others market (USD Billion)
  • Fig. 31 Generic pharmaceuticals contract manufacturing market application outlook: Segment dashboard
  • Fig. 32 Generic pharmaceuticals contract manufacturing market: Application movement analysis
  • Fig. 33 Oncology market (USD Billion)
  • Fig. 34 Immunology market (USD Billion)
  • Fig. 35 Antidiabetic market (USD Billion)
  • Fig. 36 Neurology market (USD Billion)
  • Fig. 37 Anticoagulants market (USD Billion)
  • Fig. 38 Cardiovascular market (USD Billion)
  • Fig. 39 Respiratory market (USD Billion)
  • Fig. 40 Pain market (USD Billion)
  • Fig. 41 HIV antivirals market (USD Billion)
  • Fig. 42 Others market (USD Billion)
  • Fig. 43 Regional market: Key takeaways
  • Fig. 44 Regional outlook, 2021 & 2030
  • Fig. 45 North America market, 2018 - 2030 (USD Billion)
  • Fig. 46 U.S. market, 2018 - 2030 (USD Billion)
  • Fig. 47 Canada Market, 2018 -2030 (USD Billion)
  • Fig. 48 Europe Market, 2018 -2030 (USD Billion)
  • Fig. 49 U.K. Market, 2018 -2030 (USD Billion)
  • Fig. 50 Germany Market, 2018 -2030 (USD Billion)
  • Fig. 51 France Market, 2018 -2030 (USD Billion)
  • Fig. 52 Italy Market, 2018 -2030 (USD Billion)
  • Fig. 53 SpainMarket, 2018 -2030 (USD Billion)
  • Fig. 54 The Netherlands Market, 2018 -2030 (USD Billion)
  • Fig. 55 Switzerland Market, 2018 -2030 (USD Billion)
  • Fig. 56 Sweden Market, By Service, 2018 -2030 (USD Billion)
  • Fig. 57 Asia Pacific market, 2018 - 2030 (USD Billion)
  • Fig. 58 China market, 2018 - 2030 (USD Billion)
  • Fig. 59 India market, 2018 - 2030 (USD Billion)
  • Fig. 60 Japan market, 2018 - 2030 (USD Billion)
  • Fig. 61 Australia market, 2018 - 2030 (USD Billion)
  • Fig. 62 Malaysia market, 2018 - 2030 (USD Billion)
  • Fig. 63 Indonesia market, 2018 - 2030 (USD Billion)
  • Fig. 64 Taiwan market, 2018 - 2030 (USD Billion)
  • Fig. 65 Thailand market, 2018 - 2030 (USD Billion)
  • Fig. 66 Singapore market, 2018 - 2030 (USD Billion)
  • Fig. 67 South Korea market, 2018 - 2030 (USD Billion)
  • Fig. 68 Latin America market, 2018 - 2030 (USD Billion)
  • Fig. 69 Brazil market, 2018 - 2030 (USD Billion)
  • Fig. 70 Mexico market, 2018 - 2030 (USD Billion)
  • Fig. 71 Argentina market, 2018 - 2030 (USD Billion)
  • Fig. 72 Colombia market, 2018 - 2030 (USD Billion)
  • Fig. 73 MEA market, 2018 - 2030 (USD Billion)
  • Fig. 74 South Africa market, 2018 - 2030 (USD Billion)
  • Fig. 75 Saudi Arabia market, 2018 - 2030 (USD Billion)
  • Fig. 76 Israel market, 2018 - 2030 (USD Billion)
  • Fig. 77 UAE market, 2018 - 2030 (USD Billion)
目次
Product Code: GVR-4-68039-997-7

Generic Pharmaceuticals Contract Manufacturing Market Growth & Trends:

The global generic pharmaceuticals contract manufacturing market size is expected to reach USD 106.9 billion by 2030, registering a CAGR of 5.8% over the forecast period, according to a new report by Grand View Research, Inc. Cost-saving and time-saving benefits associated with the implementation of outsourcing is responsible for driving the industry. A significant number of people globally suffer from chronic diseases. For instance, the CDC states that 6 in 10 adults in the U.S. suffer from at least one chronic disease and 4 in 10 adults suffer from two or more chronic diseases. Chronic diseases are required to be treated for a long time. The high cost of medicines is increasing the demand for cost-effective generic drugs for the treatment of chronic diseases.

This is expected to support the industry's growth post-pandemic. There is an improvement in the regulatory approval of generic drugs. For instance, in 2021, the FDA approved 93 generic drugs, and by October 2022, the regulatory authority approved over 95 generic drugs. Such improvements are expected to have a positive impact on the manufacturing of generic drugs and; thus, support the industry growth. The Japanese government is constantly trying to improve the generic pharmaceuticals market in the country. The government is also taking measures to improve the supply of generics in the country and is also encouraging medical institutes to promote the use of generic drugs.

This is expected to improve CMO activities for generics in the coming years. Global spending on medicines is also on the rise. According to the data provided in a report published by IQVIA in April 2021, global spending on medicine is expected to increase in the next 4-5 years. The report states that global spending on medicine accounted for USD 1, 265 billion in 2020 and is going to reach USD 1,580-1,610 billion by 2025. This is also expected to improve the demand for generic drugs owing to their cost efficiency, thereby supporting the industry in growth.

Generic Pharmaceuticals Contract Manufacturing Market Report Highlights:

  • The branded generics segment held the largest share in 2021due to the preference for branded generics among physicians. Some branded generic manufacturers offer benefits and gifts to physicians for boosting their product sales. This further contributes to the demand for branded generic manufacturing in the market
  • The API product segment held the largest share in 2021. The growing demand for generic drugs is supporting the demand for generic API contract manufacturing
  • The parenteral route of administration segment is expected to grow at the fastest CAGR over the forecast period due to the bioavailability of parenteral drugs over other formulations
  • The oncology segment is expected to register the fastest CAGRfrom 2022 to 2030 owing to the high cost of cancer drugs contributing to the demand for cost-effective generic medicines
  • Asia Pacific is expected to record the highest CAGR over the forecast period mainly due to the low cost of generic drug manufacturing

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Type
    • 1.1.2. Product
    • 1.1.3. Route of Administration
    • 1.1.4. Application
    • 1.1.5. Regional scope
    • 1.1.6. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Generic Pharmaceuticals Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Supportive government initiatives to improve the adoption of generic drugs
      • 3.3.1.2. Significant number of drugs losing patents
      • 3.3.1.3. Growing prevalence of chronic diseases contributing to the demand for cost-effective generics
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. Third party performance
  • 3.4. Generic pharmaceuticals contract manufacturing market Analysis Tools
    • 3.4.1. Porter's Five Forces Analysis
    • 3.4.2. PESTLE Analysis
    • 3.4.3. Major Deals & Strategic Alliances Analysis
      • 3.4.3.1. Mergers and Acquisition
      • 3.4.3.2. Expansions
      • 3.4.3.3. Agreements and Collaborations
      • 3.4.3.4. Product and Service Launches
  • 3.5. Covid-19 Impact and Reformation Strategy

Chapter 4. Generic Pharmaceuticals Contract Manufacturing Market: Drug Type Estimates & Trend Analysis

  • 4.1. Definitions and Scope
  • 4.2. Generic pharmaceuticals contract manufacturing market Share, 2021 & 2030
    • 4.2.1. Branded Generics
      • 4.2.1.1. Branded Generics market estimates and forecast 2018 to 2030 (USD Billion)
    • 4.2.2. Unbranded Generics
      • 4.2.2.1. Unbranded market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 5. Generic Pharmaceuticals Contract Manufacturing Market: Product Estimates & Trend Analysis

  • 5.1. Definitions and Scope
  • 5.2. Generic pharmaceuticals contract manufacturing market Share, 2021 & 2030
    • 5.2.1. API
      • 5.2.1.1. API market estimates and forecast 2018 to 2030 (USD Billion)
    • 5.2.2. Drug Product
      • 5.2.2.1. Drug Product market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 6. Generic Pharmaceuticals Contract Manufacturing Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Definitions and Scope
  • 6.2. Generic pharmaceuticals contract manufacturing market Share, 2021 & 2030
    • 6.2.1. Oral
      • 6.2.1.1. Oral market estimates and forecast 2018 to 2030 (USD Billion)
    • 6.2.2. Parenteral
      • 6.2.2.1. Parenteral market estimates and forecast 2018 to 2030 (USD Billion)
    • 6.2.3. Topical
      • 6.2.3.1. Topical g market estimates and forecast 2018 to 2030 (USD Billion)
    • 6.2.4. Others
      • 6.2.4.1. Others market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 7. Generic Pharmaceuticals Contract Manufacturing Market: Application Estimates & Trend Analysis

  • 7.1. Definitions and Scope
  • 7.2. Generic pharmaceuticals contract manufacturing market Share, 2021 & 2030
    • 7.2.1. Oncology
      • 7.2.1.1. Oncology market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.2. Immunology
      • 7.2.2.1. Immunology market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.3. Antidiabetic
      • 7.2.3.1. Antidiabetic market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.4. Neurology
      • 7.2.4.1. Neurology market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.5. Anticoagulants
      • 7.2.5.1. Anticoagulants market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.6. Cardiovascular
      • 7.2.6.1. Cardiovascular market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.7. Respiratory
      • 7.2.7.1. Respiratory market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.8. Pain
      • 7.2.8.1. Pain market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.9. HIV Antivirals
      • 7.2.9.1. HIV antivirals market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.10. Others
      • 7.2.10.1. Others market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 8. Generic Pharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional market share analysis, 2021 & 2030
  • 8.2. North America
    • 8.2.1. U.S.
      • 8.2.1.1. U.S. Market estimates and forecast, 2018 - 2030
    • 8.2.2. Canada
      • 8.2.2.1. Canada Market estimates and forecast, 2018 - 2030
  • 8.3. Europe
    • 8.3.1. U.K.
      • 8.3.1.1. U.K. Market estimates and forecast, 2018 - 2030
    • 8.3.2. Germany
      • 8.3.2.1. Germany Market estimates and forecast, 2018 - 2030
    • 8.3.3. France
      • 8.3.3.1. France Market estimates and forecast, 2018 - 2030
    • 8.3.4. Italy
      • 8.3.4.1. Italy Market estimates and forecast, 2018 - 2030
    • 8.3.5. Spain
      • 8.3.5.1. Spain Market estimates and forecast, 2018 - 2030
    • 8.3.6. The Netherlands
      • 8.3.6.1. The Netherlands Market estimates and forecast, 2018 - 2030
    • 8.3.7. Sweden
      • 8.3.7.1. Sweden Market estimates and forecast, 2018 - 2030
    • 8.3.8. Switzerland
      • 8.3.8.1. Switzerland Market estimates and forecast, 2018 - 2030
    • 8.3.9. Russia
      • 8.3.9.1. Russia Market estimates and forecast, 2018 - 2030
    • 8.3.10. Belgium
      • 8.3.10.1. Belgium Market estimates and forecast, 2018 - 2030
  • 8.4. Asia Pacific
    • 8.4.1. Japan
      • 8.4.1.1. Japan Market estimates and forecast, 2018 - 2030
    • 8.4.2. China
      • 8.4.2.1. China Market estimates and forecast, 2018 - 2030
    • 8.4.3. India
      • 8.4.3.1. India Market estimates and forecast, 2018 - 2030
    • 8.4.4. Australia
      • 8.4.4.1. Australia Market estimates and forecast, 2018 - 2030
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand Market estimates and forecast, 2018 - 2030
    • 8.4.7. Malaysia
      • 8.4.7.1. Malaysia Market estimates and forecast, 2018 - 2030
    • 8.4.8. New Zealand
      • 8.4.8.1. New Zealand Market estimates and forecast, 2018 - 2030
    • 8.4.9. Philippines
      • 8.4.9.1. Philippines Market estimates and forecast, 2018 - 2030
    • 8.4.10. Singapore
      • 8.4.10.1. Singapore Market estimates and forecast, 2018 - 2030
  • 8.5. Latin America
    • 8.5.1. Brazil
      • 8.5.1.1. Brazil Market estimates and forecast, 2018 - 2030
    • 8.5.2. Mexico
      • 8.5.2.1. Mexico Market estimates and forecast, 2018 - 2030
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Market estimates and forecast, 2018 - 2030
    • 8.5.4. Colombia;
      • 8.5.4.1. Colombia Market estimates and forecast, 2018 - 2030
    • 8.5.5. Chile
      • 8.5.5.1. Chile Market estimates and forecast, 2018 - 2030
  • 8.6. MEA
    • 8.6.1. South Africa
      • 8.6.1.1. South Africa Market estimates and forecast, 2018 - 2030
    • 8.6.2. Saudi Arabia
      • 8.6.2.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
    • 8.6.3. UAE
      • 8.6.3.1. UAE Market estimates and forecast, 2018 - 2030
    • 8.6.4. Israel
      • 8.6.4.1. Israel Market estimates and forecast, 2018 - 2030
    • 8.6.5. Egypt
      • 8.6.5.1. Egypt Market estimates and forecast, 2018 - 2030

Chapter 9. Competitive Analysis

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participant
  • 9.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
  • 9.3. Participant Categorization
    • 9.3.1. Innovators
      • 9.3.1.1. Recipharm AB
      • 9.3.1.2. Siegfried Holding AG
      • 9.3.1.3. Aurobindo Pharma
  • 9.4. Vendor Landscape
    • 9.4.1. List of Key Service Providers
    • 9.4.2. Market Differentiators
    • 9.4.3. Generic pharmaceuticals contract manufacturing market Share Analysis

Chapter 10. Competitive Landscape

  • 10.1. Company Profiles
    • 10.1.1. Recipharm AB
      • 10.1.1.1. Company overview
      • 10.1.1.2. Financial performance
      • 10.1.1.3. Service benchmarking
      • 10.1.1.4. Strategic initiatives
    • 10.1.2. Siegfried Holding AG
      • 10.1.2.1. Company overview
      • 10.1.2.2. Financial performance
      • 10.1.2.3. Service benchmarking
      • 10.1.2.4. Strategic initiatives
    • 10.1.3. Aurobindo Pharma
      • 10.1.3.1. Company overview
      • 10.1.3.2. Financial performance
      • 10.1.3.3. Service benchmarking
      • 10.1.3.4. Strategic initiatives
    • 10.1.4. Cambrex Corporation
      • 10.1.4.1. Company overview
      • 10.1.4.2. Financial performance
      • 10.1.4.3. Service benchmarking
      • 10.1.4.4. Strategic initiatives
    • 10.1.5. Alcami Corporation, Inc.
      • 10.1.5.1. Company overview
      • 10.1.5.2. Financial performance
      • 10.1.5.3. Service benchmarking
      • 10.1.5.4. Strategic initiatives
    • 10.1.6. Curia Global, Inc.
      • 10.1.6.1. Company overview
      • 10.1.6.2. Financial performance
      • 10.1.6.3. Service benchmarking
      • 10.1.6.4. Strategic initiatives
    • 10.1.7. Catalent, Inc
      • 10.1.7.1. Company overview
      • 10.1.7.2. Financial performance
      • 10.1.7.3. Service benchmarking
      • 10.1.7.4. Strategic initiatives
    • 10.1.8. Acme Generics Pvt Ltd.
      • 10.1.8.1. Company overview
      • 10.1.8.2. Financial performance
      • 10.1.8.3. Service benchmarking
      • 10.1.8.4. Strategic initiatives
    • 10.1.9. Metric Contract Services
      • 10.1.9.1. Company overview
      • 10.1.9.2. Financial performance
      • 10.1.9.3. Service benchmarking
      • 10.1.9.4. Strategic initiatives
    • 10.1.10. Syngene International Limited
      • 10.1.10.1. Company overview
      • 10.1.10.2. Financial performance
      • 10.1.10.3. Service benchmarking
      • 10.1.10.4. Strategic initiatives
    • 10.1.11. Pfizer CentreOne;
      • 10.1.11.1. Company overview
      • 10.1.11.2. Financial performance
      • 10.1.11.3. Service benchmarking
      • 10.1.11.4. Strategic initiatives